BioMed Research International

BioMed Research International / 2014 / Article
Special Issue

Immunology and Cell Biology of Parasitic Diseases 2014

View this Special Issue

Research Article | Open Access

Volume 2014 |Article ID 326860 | 9 pages | https://doi.org/10.1155/2014/326860

Protective Effect of a Prime-Boost Strategy with the Ts87 Vaccine against Trichinella spiralis Infection in Mice

Academic Editor: Miriam Rodriguez-Sosa
Received22 Jun 2014
Accepted18 Aug 2014
Published28 Aug 2014

Abstract

Trichinellosis is a widespread zoonosis primarily caused by Trichinella spiralis. Mucosal immunity is crucial for preventing Trichinella spiralis infection. In our previous study, a DNA vaccine with the Trichinella antigen Ts87 delivered by an attenuated Salmonella typhimurium elicited partial protection against Trichinella spiralis infection in mice. In the current study, to elicit a more robust immune response and develop a potent vaccination strategy against trichinellosis, a heterologous prime-boost vaccination regimen for Ts87 was used in mice and the protective efficacy was evaluated compared to the homologous DNA prime-boost or protein prime-boost immunization alone. The results revealed that the DNA-prime/protein-boost vaccination with Ts87 induced higher levels of both humoral and cellular immune responses. The challenge results showed that mice with the DNA-prime/protein-boost vaccination displayed higher muscle larval reduction than those immunized with DNA prime-boost or protein prime-boost. The results demonstrated that mice vaccinated with Ts87 in a DNA-prime/protein-boost strategy effectively elicited a local IgA response and mixed Th1/Th2 immune response that might be responsible for improved protection against Trichinella spiralis infection.

1. Introduction

Trichinellosis is a major food-borne zoonosis and human infection has been reported in 55 countries around the world [1]. Human trichinellosis is characterized by high fever, facial edema, and myositis, which may be serious, particularly in elderly patients [2]. The nematode Trichinella spiralis is the most common cause of human trichinellosis [3]. Outbreaks of trichinellosis have been regularly reported during the past two centuries and this parasitic disease is emerging or reemerging in some areas of the world [46]. Trichinellosis is not only a public health hazard but also an economic problem for livestock production and food safety [7]. Consequently, there is an urgent need for vaccines to control the infection.

The occurrence of trichinellosis in humans is strictly related to cultural food practices, including the consumption of raw or undercooked meat containing encapsulated Trichinella parasite larvae [7]. The infective muscle larvae are released from the muscle tissue in the stomach and migrate to the small intestine where the larvae develop into adult worms. The adult females produce newborn larvae, which penetrate the intestine and migrate to muscle tissue where they form cysts. Therefore, the intestinal mucosa is likely to be the first barrier in protecting the host against Trichinella infection. In our previous studies, an immunodominant antigen, Ts87, was cloned from T. spiralis [8], and vaccination with the recombinant Ts87 protein (rTs87) produced partial protection in immunized mice [9, 10]. To induce an IgA response in the intestinal mucosa, the Ts87 DNA was transformed into attenuated S. typhimurium. Mice vaccinated orally with the attenuated Salmonella-delivered Ts87 DNA vaccine exhibited a strong local IgA response and partial protection against T. spiralis infection [11].

Although the mucosal immunity induced by the attenuated Salmonella-delivered DNA vaccine produced partial protection against Trichinella infection, the systemic immune response to the Ts87 DNA vaccination was not high enough and the elicited protection was limited [11]. An effective vaccine usually requires a more optimal immunization regimen in the form of a prime-boost. A heterologous prime-boost regimen can be more immunogenic than a homologous prime-boost regimen [12]. In recent years, many promising results and significant protection have been reported for viral, bacterial, and parasitic infections using the heterologous prime-boost regimen [1315]. In this study, to elicit a more robust immune response, including local mucosal IgA production and a more potent vaccination strategy against Trichinellosis, a heterologous prime-boost vaccination regimen with Ts87 DNA and rTs87 was used and the protective immunity induced by this regimen was evaluated.

2. Materials and Methods

2.1. Parasites

T. spiralis (ISS 533) parasites were originally isolated from a swine source in the Heilongjiang province of China and maintained by serial passage in female ICR mice. Each mouse was orally infected with 400 T. spiralis larvae. The muscle larvae (ML) were recovered from infected mice using a modified pepsin-hydrochloric acid digestion method as described by Gamble et al. [16, 17].

2.2. Mice/Ethics Statement

Female, 6-7 week-old BALB/c mice were purchased from the Laboratory Animal Services Center of Capital Medical University (Beijing, China). All experimental procedures were reviewed and approved by the Capital Medical University Animal Care and Use Committee and were consistent with the NIH Guidelines for the Care and Use of Laboratory Animals.

2.3. Ts87 DNA Vaccine

DNA encoding the full-length Ts87 was cloned into the eukaryotic expression vector pVAX1, and the recombinant pVAX1-Ts87 plasmid DNA was transformed into an attenuated S. typhimurium SL7207 strain as a DNA vaccine (SL7207/pVAX1-Ts87) as described previously [11].

2.4. Recombinant Ts87 Protein (rTs87)

The rTs87 was expressed in E. coli BL21 (DE3) with a His-tag at the C-terminus and was purified using Ni-affinity chromatography (Novagen, USA) as described previously [11].

2.5. Immunization Regimens

In this study, BALB/c mice were vaccinated with either rTs87 or Ts87 DNA transformed attenuated S. typhimurium with different prime-boost strategies. For the DNA prime-protein boost regimen, a group of 12 mice were immunized orally with 1 × 108 cells of SL7207/pVAX1-Ts87 as described previously [11] and then boosted twice at 2-week intervals with 100 μg rTs87 emulsified with the water-in-oil adjuvant ISA 50 V2 (SEPPIC, France) intramuscularly [18]. All prime-boost regimens are described in Table 1. Two weeks after the last boost, six mice from each group were sacrificed. The serum, intestinal lavage fluid, spleen, and mesenteric lymph nodes (MLNs) were collected to evaluate the humoral and cellular immune responses. Mice immunized three times with PBS were used as a blank control.


Group (prime_boost)Prime1st boost2nd boost

DNA + PSL7207/pVAX1-Ts87 (orally)rTs87 (intramuscularly)rTs87 (intramuscularly)
DNA + DNASL7207/pVAX1-Ts87 (orally)SL7207/pVAX1-Ts87 (orally)SL7207/pVAX1-Ts87 (orally)
P + PrTs87 (intramuscularly)rTs87 (intramuscularly)rTs87 (intramuscularly)
PBSPBSPBSPBS

2.6. Antibody Responses

The levels of antigen-specific total IgG and subtype IgG1 and IgG2a antibodies in the sera of the immunized mice were determined using a modified indirect enzyme-linked immunosorbent assay (ELISA) as described previously [19]. Briefly, 96-well microtiter plates (Costar) were coated with rTs87 (10 μg/mL) and blocked with 5% fetal bovine serum (FBS) in PBS. For total IgG detection, the plates were incubated with sera at different dilution and then incubated with HRP-conjugated goat anti-mouse IgG. For the isotype-specific ELISA, after incubation with the mouse sera samples (1 : 200 dilution), the plates were incubated with goat anti-mouse IgG1 or IgG2a (BD Pharmingen, USA). Then, HRP-conjugated rabbit anti-goat IgG antibodies (BD Biosciences, USA) were added. The ELISA plates were developed with o-phenylenediamine dihydrochloride substrate (OPD, Sigma, USA) and read at 492 nm.

2.7. Measurement of Total IgA in Intestinal Washes

The intestinal lavage fluid was prepared as described previously [11]. Briefly, for each sacrificed mouse, 10 cm of the small intestine beginning at the gastroduodenal junction was cut, and the interior of the small intestine was flushed twice with a total of 2 mL of cold PBS. After centrifugation at 800 ×g for 10 min, the supernatants were harvested and stored at −80°C until use. The total intestinal IgA was assessed with a sandwich-type ELISA by trapping the intestinal mucosal IgA as described previously [20].

2.8. T Cell Proliferation

A T cell proliferation assay was performed using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, USA). Briefly, 5 × 105 splenocytes in 100 μL of RPMI-1640 were in vitro stimulated with 100 μL of rTs87 (10 μg/mL) for 72 h. Then, 40 μL of the CellTiter 96 AQueous One Solution Reagent was added to each well and incubated for 1–4 hours at 37°C. The stimulation index (SI) was calculated as the ratio of the mean absorbance of the stimulated/unstimulated wells.

2.9. Cytokine Assays

An enzyme-linked immunospot assay (ELISPOT) was used to detect IFN-γ, IL-4, IL-6, and IL-10 secreted by the lymphocytes isolated from the spleen and MLNs of immunized mice according to the manufacturer’s instructions (BD Biosciences, USA) [21]. Briefly, the mice were sacrificed two weeks after the last boost and the lymphocytes from the spleen and the MLNs were aseptically isolated. The wells of MultiScreen-IP Filter Plates for ELISPOT (Millipore, USA) were coated with the capture antibody (anti-mouse IFN-γ, IL-4, IL-6, and IL-10; BD Biosciences, USA) at a 1 : 200 dilution in PBS and incubated overnight at 4°C. The plates were washed once with RPMI 1640 medium (Gibco, USA) with 10% FBS and blocked with the same medium for 2 h at room temperature. A total of 1 × 106 lymphocytes for IL-4, IL-6, and IL-10 or 5 × 105 lymphocytes for IFN-γ were added to each well. The rTs87 was added to the well at a final concentration of 10 μg/mL and stimulated for 48 h. Concanavalin A (ConA, Sigma, USA; 5 μg/mL) was used as a nonspecific positive control. The detection antibody (biotinylated anti-IFN-γ, IL-4, IL-6, and IL-10 antibody; BD Biosciences Pharmingen, USA) was added at 1 : 200 in 100 μL of dilution buffer (PBS containing 10% FBS) and incubation was continued for 2 h. After incubation with 100 μL of streptavidin-HRP for 1 h (BD Biosciences, USA), the plates were developed with 100 μL of a 3-amino-9-ethylcarbazole substrate solution (20 μL of an AEC chromogen for each 1 mL of substrate, BD ELISPOT AEC substrate set; BD Biosciences, USA) for 1–5 min. The spots corresponding to the number of IFN-γ, IL-4, IL-6, and IL-10-secreting cells were counted automatically with a CTL ELISPOT reader and analyzed using the ImmunoSpot image analyzer software v4.0.

2.10. Evaluation of Larval Burden

Two weeks after the final boost, the remaining 6 mice from each group were challenged with 400 T. spiralis muscle larvae. Six weeks after the challenge, the mice were sacrificed. The larvae in the muscle from each mouse were collected and counted as described previously [17]. Reductions in the larval burden were calculated as follows: worm burden reduction rate (%) = (1 − mean number of larvae per gram muscle in vaccinated mice/mean number of larvae per gram muscle in control mice) × 100%.

2.11. Statistical Analysis

All of the data were evaluated by one-way ANOVA using the SPSS 17.0 software. The data are expressed as the means ± standard error (SE). was considered statistically significant.

3. Results

3.1. Serological Immune Response

Mice immunized orally with Ts87 DNA-attenuated S. typhimurium (DNA) and then boosted intramuscularly twice with rTs87 (P) produced much higher levels of total IgG, IgG1, and IgG2a compared to the group boosted with Ts87 DNA alone (, Figure 1). The group immunized with rTs87 and boosted with the same protein twice also produced high levels of total IgG, IgG1, and IgG2a. The production of IgG1 and IgG2a indicates a mixed Th1(IgG2a) or Th2-like (IgG1) responses, with Th2 predominant.

3.2. Mucosal IgA Response

The total intestinal mucosa IgA was measured by sandwich ELISA. The secretory IgA level was significantly increased in the mucosa of mice immunized orally with the Ts87 DNA vaccine, either boosted with the same DNA (DNA + DNA) or with the recombinant protein (DNA + P) compared to the group with the protein prime-boost (P + P). However, the highest level of secretory IgA was observed in the DNA immunized group boosted with the same DNA carried with Salmonella bacteria compared to the protein boosted group () (Figure 2). There was no significant secretion of mucosal IgA in protein immunized group compared to the PBS control group.

3.3. Cytokine Profiles

The ELISPOT assay was used to detect the cytokines IFN-γ, IL-4, IL-6, and IL-10 secreted by the lymphocytes isolated from the spleen and MLNs two weeks after the 3rd immunization. The IFN-γ and IL-6 levels were significantly increased in the lymphocytes isolated from both the spleen and MLNs of mice immunized with the Ts87 DNA-prime/protein-boost compared to homologous prime-boost immunization regimens (Figures 3(a), 3(c), 4(a), and 4(c)). The IL-4 level was significantly increased in the groups immunized with the DNA-prime/protein-boost or the protein prime-boost in splenocytes compared to the groups immunized with the DNA prime-boost or PBS control (Figure 3(b)). However, the secretion of IL-4 was hardly tested in the MLN cells (less than five spots, Figure 4(b)). Although a higher level of IL-10 was consistently observed in the group immunized with the rTs87 protein prime-boost compared to the other immunization groups, this change was not statistically significant (Figures 3(d) and 4(d)). No spots were detected in the unstimulated lymphocytes, whereas the positive spots were all high without exception in the ConA stimulated control groups (up to 400/5 × 105 cells, data not shown).

3.4. Proliferative Responses of T Cells

The rTs87-stimulated T cell proliferation of the splenocytes isolated from the DNA-prime/protein-boost mice was significantly higher than the other three groups (), indicating that heterologous immunization with a DNA vaccine-prime and recombinant protein-boost greatly enhanced the antigen-specific T cell proliferative response against rTs87 (Figure 5).

3.5. Protective Immunity

In comparison to the PBS control group, mice immunized with DNA prime-protein boost, DNA prime-boost, and protein prime-boost experienced 46.1%, 36.2%, and 24.6% reduction in muscle larval burden, respectively (Figure 6). There is a significant difference between the heterologous prime-boost vaccination regimen and the homologous DNA prime-boost () or between the heterologous prime-boost vaccination regimen and homologous protein prime-boost immunization (). These results indicate that the DNAprime/protein-boost vaccination induced significantly better protective immunity than the homologous DNA prime-boost or protein prime-boost regimens against T. spiralis infection in BALB/c mice.

4. Discussion

DNA vaccination becomes more attractive because of its ability to induce a broad range of immune responses and long-lasting immunity. However, DNA vaccines remain poorly immunogenic compared to protein vaccines [22]. An effective vaccine usually requires more than one immunization in the form of a prime-boost. Traditionally, the same vaccines are administered multiple times as homologous boosts. New findings suggest that the prime-boost can be performed with different types of vaccines containing the same antigens. This type of heterologous prime-boost can be more immunogenic than the homologous prime-boost and may elicit unique immune responses allowing for improved immunogenicity and/or protection against viral, bacterial, and parasitic infections [21, 2325].

The DNA plus protein vaccination strategy utilizes the benefits of DNA and protein vaccines to effectively induce both cell-mediated immunity and antibody responses against invading organisms [26]. Human studies have also shown superior immune responses during mixed modality prime-boost [27, 28]. The objective of the present study was to explore the protective efficacy and characteristics of the immune response elicited by a DNA prime followed by a protein boost compared to a homologous DNA or protein immunization alone. The kinetics of the mucosal and systemic antibody secretion, patterns of antibody subtype production, cytokine production by the spleen, MLN lymphocyte, and protective effect of this DNA-prime/protein-boost regimen against T. spiralis infection were evaluated in mice in this study.

Mucosal immune responses act as the first barrier of defense against T. spiralis. The mucosal IgA response, when adequately induced, can impede the establishment of infective Trichinella parasites in the mouse intestine [29]. Intranasal immunization with a 30-mer peptide of a 43 kDa Trichinella antigen induced protective immunity against T. spiralis infection accompanied by the secretion of mucosal IgA [30]. Intraperitoneal injection of an IgA monoclonal antibody against the Trichinella parasite also protected mice from infection with infective larva [29]. The DNA vaccine delivered by attenuated S. typhimurium produced long-lasting mucosal IgA and systemic immune responses and provides an efficient vaccination platform, particularly for intestinal infections in which local immunity is essential for protection [3133]. In our previous study, oral vaccination with Ts87 DNA delivered by S. typhimurium induced significant intestinal IgA secretion and considerable protective immunity against the challenge of T. spiralis infective larva [11]. Compared to the homologous DNA prime-boost vaccination, the heterologous Ts87 DNA-prime and protein-boost regimen examined in this study produced significant high level of systemic antibody responses, including increased total IgG and subtypes IgG1 and IgG2a and significantly greater protection against T. spiralis larval challenge compared to homologous DNA or protein prime-boost regimens. The greater protection in the mice immunized with the Ts87 DNA-prime and protein-boost regimen (46.1%) compared to the mice immunized with the homologous DNA prime-boost (36.2%) is also associated with more robust cellular responses demonstrated by greater lymphocyte proliferation upon specific antigen stimulation and the higher level of INF-γ secreted by both splenocytes and MLNs. It has been demonstrated that the combined Th1 and Th2 immune responses are important for immunity against T. spiralis infection [19, 34, 35], even though it is believed that the Th2 response is essential for protective immunity to gastrointestinal (GI) helminth infections [36]. In this study, mice immunized with the DNA-prime/protein-boost produced not only a stronger Th2-associated immune response (IgG1 antibody, secretory mucosal IgA, IL-4, and IL-6), but also a Th1-like response evidenced by high titers of IgG2a antibody and IFN-γ. The results indicate that this heterologous immunization regimen of a DNA-prime/protein-boost with a Ts87 vaccine produced a mixed Th1 and Th2 immune response that may contribute to greater protection than homologous DNA or protein prime-boost alone.

High levels of IgA secretion in the mucosal tissue were also observed in the mice vaccinated with the oral Ts87 DNA-prime and intramuscular protein-boost, although the IgA level was not as high as those orally vaccinated three times with Ts87 DNA. IL-4, IL-6, and IL-10 are associated with murine IgA responses [37]. IL-6 has been identified to be the most effective terminal differentiation factor for IgA-committed B cells to become IgA-producing cells in both human and mouse systems [38]. In this study, we also observed high levels of IL-6 secreted by splenocytes and MLNs from mice vaccinated with the Ts87 DNA-prime/protein-boost than other groups with homologous prime-boost vaccination regimens. Significantly higher levels of IL-4 were secreted by the splenocytes in the mice vaccinated with the DNA-prime/protein-boost and protein prime-boost than those vaccinated with the DNA prime-boost or PBS control. Although it is believed that IL-10 plays an essential role in IgA B-cell differentiation in humans [39], in the present study, there was no significant difference in the level of IL-10 secreted by lymphocytes from the mice vaccinated with the DNA-prime/protein-boost regimen and the other immunization regimens. High levels of IL-6 correlated with the elevated intestinal mucosal IgA level upon DNA-prime/protein-boost immunization, indicating that IL-6 may contribute more to the intestinal mucosa IgA response.

In conclusion, the objective of this study was to improve the efficacy of the Ts87 vaccine using a heterologous prime-boost vaccination strategy. The results revealed that the DNA-prime/protein-boost vaccination regimen for Ts87 induced both humoral and cellular immune responses against T. spiralis infection, which was associated with high levels of mucosal secreted IgA, serological IgG (total IgG, IgG1, and IgG2a), and lymphocyte secreted IFN-γ, IL-4, and IL-6. Challenge experiments further demonstrated that the DNA-prime/protein-boost vaccination with Ts87 produced significantly greater muscle larval reduction than the traditional homologous prime-boost vaccination. Therefore, the Ts87 vaccine using DNA-prime/protein-boost vaccination produced more effective vaccine efficacy against trichinellosis. Additional studies are needed including optimizing the inoculation dosage, route, immunization sequence, and timing of delivery for this prime-boost vaccination strategy.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (81171598, 81371837, and 81201312), the National Science and Technology Major Project (2012ZX10004220-012), Training Program Foundation for the Beijing Municipal Excellent Talents (2012D005018000009), Collaborative Innovation Center of Infectious Diseases, and the Importation and Development of High-Caliber Talents Project of Beijing Municipal Institutions (IDHT20140212).

References

  1. E. Pozio, “World distribution of Trichinella spp. infections in animals and humans,” Veterinary Parasitology, vol. 149, no. 1-2, pp. 3–21, 2007. View at: Google Scholar
  2. E. Pozio, M. A. Gomez Morales, and J. Dupouy-Camet, “Clinical aspects, diagnosis and treatment of trichinellosis,” Expert Review of Anti-Infective Therapy, vol. 1, no. 3, pp. 471–482, 2003. View at: Publisher Site | Google Scholar
  3. M. Mitreva, D. P. Jasmer, D. S. Zarlenga et al., “The draft genome of the parasitic nematode Trichinella spiralis,” Nature Genetics, vol. 43, no. 3, pp. 228–235, 2011. View at: Publisher Site | Google Scholar
  4. J. Dupouy-Camet, “Trichinellosis: a worldwide zoonosis,” Veterinary Parasitology, vol. 93, no. 3-4, pp. 191–200, 2000. View at: Publisher Site | Google Scholar
  5. Z. Q. Wang, J. Cui, and B. L. Xu, “The epidemiology of human trichinellosis in China during 2000–2003,” Acta Tropica, vol. 97, no. 3, pp. 247–251, 2006. View at: Publisher Site | Google Scholar
  6. K. D. Murrell and E. Pozio, “Trichinellosis: the zoonosis that won't go quietly,” International Journal for Parasitology, vol. 30, no. 12-13, pp. 1339–1349, 2000. View at: Publisher Site | Google Scholar
  7. P. Dorny, N. Praet, N. Deckers, and S. Gabriel, “Emerging food-borne parasites,” Veterinary Parasitology, vol. 163, no. 3, pp. 196–206, 2009. View at: Publisher Site | Google Scholar
  8. Y. Yang, X. Zhu, J. Yang, L. Zhou, and S. Huang, “Immunoscreening and Sequence Analysis of a cDNA Library of Adult Trichinella spiralis,” Chinese Journal of Parasitology and Parasitic Diseases, no. 05, pp. 16–19, 2002. View at: Google Scholar
  9. X.-P. Zhu, J. Yang, Y.-P. Yang et al., “Prokaryotic expression and characterization of an antigenic gene of adult Trichinella spiralis,” Chinese Journal of Parasitology & Parasitic Diseases, vol. 21, no. 1, pp. 16–19, 2003. View at: Google Scholar
  10. Q. Li, J. Yang, Y.-P. Yang et al., “Effect of different adjuvant formulations on the induced protection of mice immunized with recombinant protein ts87 of Trichinella spiralis,” Chinese Journal of Parasitology & Parasitic Diseases, vol. 25, no. 2, pp. 101–105, 2007. View at: Google Scholar
  11. Y. Yang, Z. Zhang, J. Yang, X. Chen, S. Cui, and X. Zhu, “Oral vaccination with Ts87 DNA vaccine delivered by attenuated Salmonella typhimurium elicits a protective immune response against Trichinella spiralis larval challenge,” Vaccine, vol. 28, no. 15, pp. 2735–2742, 2010. View at: Publisher Site | Google Scholar
  12. S. Lu, “Heterologous prime-boost vaccination,” Current Opinion in Immunology, vol. 21, no. 3, pp. 346–351, 2009. View at: Publisher Site | Google Scholar
  13. J. Min, D. Qu, C. Li et al., “Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategy,” Vaccine, vol. 30, no. 38, pp. 5631–5636, 2012. View at: Publisher Site | Google Scholar
  14. C. A. M. Alvarez, A. Vaquero-Vera, R. Fonseca-Liñán, F. Ruiz-Pérez, N. Villegas-Sepúlveda, and G. Ortega-Pierres, “A prime-boost vaccination of mice with attenuated Salmonella expressing a 30-mer peptide from the Trichinella spiralis gp43 antigen,” Veterinary Parasitology, vol. 194, no. 2-4, pp. 202–206, 2013. View at: Publisher Site | Google Scholar
  15. G. Feng, Q. Jiang, M. Xia et al., “Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection,” PLoS ONE, vol. 8, no. 4, Article ID e61135, 2013. View at: Publisher Site | Google Scholar
  16. H. R. Gamble, A. S. Bessonov, K. Cuperlovic et al., “International Commission on Trichinellosis: recommendations on methods for the control of Trichinella in domestic and wild animals intended for human consumption,” Veterinary Parasitology, vol. 93, no. 3-4, pp. 393–408, 2000. View at: Publisher Site | Google Scholar
  17. Y. Gu, J. Wei, J. Yang et al., “Protective immunity against Trichinella spiralis infection induced by a multi-epitope vaccine in a murine model,” PLoS ONE, vol. 8, no. 10, Article ID e77238, 2013. View at: Google Scholar
  18. T. L. Fodey, P. Delahaut, C. Charlier, and C. T. Elliott, “Comparison of three adjuvants used to produce polyclonal antibodies to veterinary drugs,” Veterinary Immunology and Immunopathology, vol. 122, no. 1-2, pp. 25–34, 2008. View at: Publisher Site | Google Scholar
  19. J. Yang, Y. Yang, Y. Gu et al., “Identification and characterization of a full-length cDNA encoding paramyosin of Trichinella spiralis,” Biochemical and Biophysical Research Communications, vol. 365, no. 3, pp. 528–533, 2008. View at: Publisher Site | Google Scholar
  20. J. Fan, Y. Xie, X. Li et al., “The influence of Peyer's patch apoptosis on intestinal mucosal immunity in burned mice,” Burns, vol. 35, no. 5, pp. 687–694, 2009. View at: Publisher Site | Google Scholar
  21. R. Suppian and N. Mohd Nor, “Induction of an antibody response against Plasmodium falciparum F2RIIEBA by heterologous prime-boost immunisation,” Tropical Life Sciences Research, vol. 24, no. 1, pp. 9–18, 2013. View at: Google Scholar
  22. L. Li, F. Saade, and N. Petrovsky, “The future of human DNA vaccines,” Journal of Biotechnology, vol. 162, no. 2, pp. 171–182, 2012. View at: Publisher Site | Google Scholar
  23. S. Cao, A. A. Mousa, G. O. Aboge et al., “Prime-boost vaccination with plasmid DNA followed by recombinant vaccinia virus expressing BgGARP induced a partial protective immunity to inhibit Babesia gibsoni proliferation in dogs,” Acta Parasitologica, vol. 58, no. 4, pp. 619–623, 2013. View at: Google Scholar
  24. A. Gil, S. Shen, S. Coley et al., “DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus,” Human Vaccines & Immunotherapeutics, vol. 9, no. 10, pp. 2120–2132, 2013. View at: Google Scholar
  25. S. Mazumder, M. Maji, A. Das, and N. Ali, “Potency, efficacy and durability of DNA/DNA, DNA/ protein and protein/protein based vaccination using gp63 against Leishmania donovani in BALB/c mice,” PLoS ONE, vol. 6, no. 2, Article ID e14644, 2011. View at: Publisher Site | Google Scholar
  26. S. Lu, “Combination DNA plus protein HIV vaccines,” Springer Seminars in Immunopathology, vol. 28, no. 3, pp. 255–265, 2006. View at: Publisher Site | Google Scholar
  27. G. J. Churchyard, C. Morgan, E. Adams et al., “A phase iia randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade RAD5 HIV-1 vaccine boost in healthy adults (HVTN204),” PLoS ONE, vol. 6, no. 8, Article ID e21225, 2011. View at: Publisher Site | Google Scholar
  28. J. E. Ledgerwood, C.-J. Wei, Z. Hu et al., “DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials,” The Lancet Infectious Diseases, vol. 11, no. 12, pp. 916–924, 2011. View at: Publisher Site | Google Scholar
  29. T. Inaba, H. Sato, and H. Kamiya, “Monoclonal IgA antibody-mediated expulsion of Trichinella from the intestine of mice,” Parasitology, vol. 126, no. part 6, pp. 591–598, 2003. View at: Publisher Site | Google Scholar
  30. C. McGuire, W. C. Chan, and D. Wakelin, “Nasal immunization with homogenate and peptide antigens induces protective immunity against Trichinella spiralis,” Infection and Immunity, vol. 70, no. 12, pp. 7149–7152, 2002. View at: Publisher Site | Google Scholar
  31. S. Spreng, G. Dietrich, and G. Weidinger, “Rational design of Salmonella-based vaccination strategies,” Methods, vol. 38, no. 2, pp. 133–143, 2006. View at: Publisher Site | Google Scholar
  32. L. Pathangey, J. J. Kohler, R. Isoda, and T. A. Brown, “Effect of expression level on immune responses to recombinant oral Salmonella enterica serovar Typhimurium vaccines,” Vaccine, vol. 27, no. 20, pp. 2707–2711, 2009. View at: Publisher Site | Google Scholar
  33. J. J. Kohler, L. Pathangey, A. Hasona, A. Progulske-Fox, and T. A. Brown, “Long-term immunological memory induced by recombinant oral Salmonella vaccine vectors,” Infection and Immunity, vol. 68, no. 7, pp. 4370–4373, 2000. View at: Publisher Site | Google Scholar
  34. M. Kołodziej-Sobocińska, E. Dvoroznakova, and E. Dziemian, “Trichinella spiralis: macrophage activity and antibody response in chronic murine infection,” Experimental Parasitology, vol. 112, no. 1, pp. 52–62, 2006. View at: Publisher Site | Google Scholar
  35. S. Deville, A. de Pooter, J. Aucouturier et al., “Influence of adjuvant formulation on the induced protection of mice immunized with total soluble antigen of Trichinella spiralis,” Veterinary Parasitology, vol. 132, no. 1-2, pp. 75–80, 2005. View at: Publisher Site | Google Scholar
  36. H. E. Scales, M. X. Ierna, and C. E. Lawrence, “The role of IL-4, IL-13 and IL-4Rα in the development of protective and pathological responses to Trichinella spiralis,” Parasite Immunology, vol. 29, no. 2, pp. 81–91, 2007. View at: Publisher Site | Google Scholar
  37. M. Yamamoto, J. L. Vancott, N. Okahashi et al., “The role of Th1 and Th2 cells for mucosal IgA responses,” Annals of the New York Academy of Sciences, vol. 778, pp. 64–71, 1996. View at: Publisher Site | Google Scholar
  38. K. W. Beagley, J. H. Eldridge, F. Lee et al., “Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells,” Journal of Experimental Medicine, vol. 169, no. 6, pp. 2133–2148, 1989. View at: Publisher Site | Google Scholar
  39. F. Brière, J.-M. Bridon, D. Chevet et al., “Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA,” Journal of Clinical Investigation, vol. 94, no. 1, pp. 97–104, 1994. View at: Publisher Site | Google Scholar

Copyright © 2014 Yuan Gu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

905 Views | 402 Downloads | 8 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.